Fady Jamous, MD
Pulmonary Disease · Sioux Falls, SDNPI 1912973785
Payments from drug & device makers
What this record shows
The money is spread across several categories — travel and lodging (57.4%), education and food and beverage — rather than concentrated in one kind of arrangement. Intuitive Surgical accounts for 92.7% of it on its own, with 7 other manufacturers making up the rest.
Across 31 payments — averaging $190.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$5K
- Boehringer Ingelheim$129
- Jazz Pharmaceuticals Inc.$122
- Insmed, Inc.$66
- CSL Behring$63
- Inspire Medical Systems, Inc.$22
- plus $26 from 2 others
Across 10 payments — averaging $4985.51 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Cumberland Pharmaceuticals, Inc.$36K
- Astrazeneca UK Limited$14K
What the payments were for
- Travel & lodging$3,37857%
- Food & beverage$86915%
- Education$1,64228%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 20 | $5,461 |
| Boehringer Ingelheim | 1 | $129 |
| Jazz Pharmaceuticals Inc. | 1 | $122 |
| Insmed, Inc. | 4 | $66 |
| CSL Behring | 2 | $63 |
| Inspire Medical Systems, Inc. | 1 | $22 |
| Sunovion Pharmaceuticals Inc. | 1 | $13 |
| Merck | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Da Vinci Surgical System$4,923
- XYWAV$122
How this compares
$5,890 in reported general payments places this provider in the 75th percentile of 35 pulmonary disease providers in South Dakota.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Aralast NpAlpha-1-Proteinase Inhibitor | 12 | $214,005 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 265 | $196,419 |
| Pirfenidone | 14 | $97,679 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 127 | $62,453 |
| Dupixent SyringeDupilumab | 12 | $44,904 |
| Breo ElliptaFluticasone/Vilanterol | 68 | $28,564 |
| Incruse ElliptaUmeclidinium Bromide | 61 | $23,744 |
| Spiriva HandihalerTiotropium Bromide | 35 | $23,515 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 26 | $21,819 |
| SymbicortBudesonide/Formoterol Fumarate | 32 | $12,046 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 13 | $10,009 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 102 | $9,638 |
| Arnuity ElliptaFluticasone Furoate | 33 | $7,391 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 11 | $7,377 |
| Advair HfaFluticasone Propion/Salmeterol | 11 | $6,385 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimStiolto Respimat, Combivent Respimat | $129 | $17,38624 claims |
| MerckDulera | $13 | $4,65113 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 35 pulmonary disease providers in South Dakota.
Other pulmonary disease in Sioux Falls
- Joevasanth DevasahayamSioux Falls$8K
- Matthew TaylorSioux Falls$8K
- Rizan HajalSioux Falls$5K
- Kaitlin BranickSioux Falls$5K
- Anna PlemmonsSioux Falls$3K
- Mohammed AwadSioux Falls$2K
- Ashraf ElshamiSioux Falls$2K
- John YuSioux Falls$2K
- Rajaganesh RajagopalanSioux Falls$964
- Ross BaconSioux Falls$599
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.